Document is current
Any future updates will be listed below
-
Authors
Lee, Valerie
Sachidanand, Apoorvaa S. https://orcid.org/0009-0001-6315-992X
Rodriguez, Christina
Wang, Junke
Onners, Beth
Qi, Hanfei https://orcid.org/0000-0002-0072-5752
Parkinson, Rose
McPhaul, Thomas
Durham, Jennifer
Ding, Ding
Hacker-Prietz, Amy
Narang, Amol K.
Le, Dung T. https://orcid.org/0000-0002-2110-7697
De Jesus, Ana
Pishvaian, Michael https://orcid.org/0000-0002-1165-9041
Christenson, Eric
Thompson, Elizabeth D. https://orcid.org/0000-0001-8464-9904
Anders, Robert A.
Osipov, Arsen
Weiss, Matthew
Burns, William
Burkhart, Richard
Lafaro, Kelly
He, Jin
Wolfgang, Christopher L.
Sugar, Elizabeth
Herman, Joseph M.
Jaffee, Elizabeth M. https://orcid.org/0000-0003-3841-6549
Wang, Hao https://orcid.org/0000-0001-6489-6940
Laheru, Daniel A. https://orcid.org/0000-0001-6646-0200
Zheng, Lei https://orcid.org/0000-0003-4163-2541
- License Information
-
More Information
Article History
Received: 24 April 2025
Accepted: 27 January 2026
First Online: 18 March 2026
Competing interests
: L.Z. receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, Halozyme, and Abmeta. L.Z. is a paid consultant/Advisory Board member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Natera, Novagenesis, Snow Lake Capitals, BioArdis, Tempus, Amberstone, Pfizer, Tavotek, and Mingruizhiyao. L.Z. holds shares at Alphamab, Amberstone, and Mingruizhiyao. E.M.J. receives grant support from the Lustgarten Foundation, Bristol-Meyers Squibb, Genentech, and AstraZeneca; is a paid consultant for NextCure, Genocea, DragonFly, Stimit, CSTONE, Achilles, and Candel; is on the advisory board of Parker Institute and Break Through Cancer; is a founder of Abmeta Biotech; and is the Chief Medical Advisor for the Lustgarten Foundation. J.M.H consults and holds equity from Histosonics, consults for BTG, and receives research support to the Northwell Health System from Canopy Cancer Collective/1440 Foundation. R.A.A. serves on the advisory board of RAPT Therapeutics, AstraZeneca, Merck SD, Bristol-Myers Squibb, and receives research funding from RAPT Therapeutics, Bristol-Myers Squibb and the National Institute of Health. There is no relevant conflict of interest disclosed by all other authors.
